Life Sciences

E-mails allegedly show GSK concerns about Avandia

Pharma Compliance Alert, January 21, 2009

E-mails between GlaxoSmithKline (GSK) researchers allegedly show they were concerned about the possible increase in cardiac risks associated with the company’s diabetes drug Avandia at the same time GSK publicly refuted similar conclusions in a New England Journal of Medicine article, according to a Wall Street Journal article.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular